New Drug Combination Treats Hepatitis C Patients Also Infected with HIV

Novel treatment has 97 percent success rate in co-infected patients —

Roughly 20 to 30 percent of patients with hepatitis C virus (HCV) are also infected with human immunodeficiency virus type 1 (HIV). Both blood-borne viruses share the same modes of transmission, but many HCV medications currently have significant limitations due to adverse interactions with HIV treatments. Researchers at University of California, San Diego School of Medicine report a new combination that effectively treats HCV in patients co-infected with HIV. … Read the full story from the UC San Diego News Center

David L. Wyles, MD, is lead author of the New England Journal of Medicine article that reports the results of the multi-center study. Dr. Wyles is associate professor of clinical medicine in the Division of Infectious Diseases.

Read the article online:

Wyles D.L., Ruane P.J., Sulkowski M.S., et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. New England Journal of Medicine July 21, 2015, 10.1056/NEJMoa1503153.  Free full text

UC San Diego School of Medicine Launches Hepatitis C Clinical Trials

A collaborative partnership between the UC San Diego Liver Center and Antiviral Research Center (AVRC) has resulted in 19 clinical trials for hepatitis C virus (HCV), focused on developing more effective and well-tolerated HCV treatments…. Read the full story from the UCSD Newsroom

Department of Medicine clinical trials investigators Alexander Kuo, MD, and David L. Wyles, MD, are featured in this news release.

Dr. Kuo is associate professor of medicine in the Division of Gastroenterology and medical director of the Liver Transplant Program at the UC San Diego Health System Liver Center.

Dr. Wyles, a researcher at the UC San Diego Antiviral Research Center, is associate professor of clinical medicine in the Division of Infectious Diseases.

A Boon for Hepatitis C Research: Dr. Martina Buck Develops First Tissue Culture Model

Dr. Martina Buck, faculty researcher in the Division of Gastroenterology, has developed the first tissue culture system for the Hepatitis C virus. The system offers a model in which investigators can more easily test potential treatments for Hepatitis C.

Her report of the system is published in PLoS ONE.

Martina Buck, Ph.D., is Assistant Professor of Medicine in the Division of Gastroenterology and a researcher in the Tumor Growth, Invasion and Metastasis Program at the Moores UCSD Cancer Center.

Read the full story from
UC San Diego Health Sciences Communications

Citation for the report: Buck M (2008) Direct Infection and Replication of Naturally Occurring Hepatitis C Virus Genotypes 1, 2, 3 and 4 in Normal Human Hepatocyte Cultures. PLoS ONE 3(7): e2660. doi:10.1371/journal.pone.0002660  |  Read the report (free full text)

More Information: